Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

Ovarian cancer, often diagnosed late due to subtle symptoms, sees significantly improved survival rates with early detection.

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

For ovarian cysts that cause pain, medications such as acetaminophen, ibuprofen, or another non-steroidal anti-inflammatory ...

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

The Cyprus Institute of Neurology and Genetics (CING) has launched two new research programmes to improve the classification ...

Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...